Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33,378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Symmans WF, et al. Among authors: yang w. J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135148 Free PMC article.
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Li J, et al. Among authors: yang w. Oncologist. 2011;16(12):1675-83. doi: 10.1634/theoncologist.2011-0196. Epub 2011 Dec 6. Oncologist. 2011. PMID: 22147002 Free PMC article.
Inflammatory breast cancer: what we know and what we need to learn.
Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT. Yamauchi H, et al. Among authors: yang w. Oncologist. 2012;17(7):891-9. doi: 10.1634/theoncologist.2012-0039. Epub 2012 May 14. Oncologist. 2012. PMID: 22584436 Free PMC article. Review.
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. Yam C, et al. Among authors: yang w. Invest New Drugs. 2018 Apr;36(2):299-306. doi: 10.1007/s10637-018-0564-2. Epub 2018 Jan 27. Invest New Drugs. 2018. PMID: 29374384 Clinical Trial.
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. Hatzis C, et al. Among authors: yang w. JAMA. 2011 May 11;305(18):1873-81. doi: 10.1001/jama.2011.593. JAMA. 2011. PMID: 21558518 Free PMC article.
33,378 results
You have reached the last available page of results. Please see the User Guide for more information.